MarginsXMarginsX
Home › Markets › Health Care › GLUE

Monte Rosa Therapeutics Inc. (GLUE)

GLUE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.16
-2.24% on the day
Market cap
$782.7M
Small cap
Revenue · 2025
$123.7M
+63.5% on 2024
Net income · 2025
-$38.6M
-31.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/0001193125-26-109360-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerGLUE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001826457
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$123.7M
Net income-$38.6M
Operating income-$54.2M
Net margin-31.2%
Operating margin-43.8%
Revenue growth+63.5%
Cash$129.9M
Total assets$448.7M
P/E (computed)Net income was not positive
P/S (computed)6.3×

Warning signs

Cash runway
3.3 months
$45.2M cash at September 30, 2026
Share count, 1 year
+31.2%
2025-10-31 to 2026-10-30 · +70.6% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$4.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$45.2M cash; operating cash flow -$41.4M a quarter.Report 2026-09-30
Shares outstanding85,450,119 (2026-10-30); 65,117,761 a year earlier; 50,081,023 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-01-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$54.4M$3.1M-$41.0M$45.2MNo debt tags$70.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$9.0M-$43.4M-$44.1M$90.1MNo debt tags$28.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$4.2M-$44.5M-$37.4M$159.9MNo debt tags$43.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$2.8M-$46.1M-$43.0M$129.9MNo debt tags$123.7M10-K 2026-03-17
Q3 2025
2025-09-30
$12.8M-$27.1M$100.4M$208.3MNo debt tags$181.5M10-Q 2026-11-05
Q2 2025
2025-06-30
$23.2M-$12.3M-$34.7M$69.4MNo debt tags$178.0M10-Q 2026-08-06
Q1 2025
2025-03-31
$84.9M$46.9M-$45.5M$78.5MNo debt tags$159.5M10-Q 2026-05-07
Q4 2024
2024-12-31
$60.6M$13.4M$128.9M$224.3MNo debt tags$75.6M10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-11
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 405 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.4%
1 month-5.3%
3 months-40.8%
Year to date-40.2%
1 year-34.6%
From 52-week high-63.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
PRMEPrime Medicine Inc.$4.19-1.87%$762.3M
AURAAura Biosciences Inc.$7.22+1.55%$751.4M
SLDBSolid Biosciences Inc.$6.48-5.26%$723.2M
MGTXMeiraGTx Holdings plc$8.74-4.79%$854.2M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
IMTXImmatics N.V.$6.17-3.44%$923.2M
ODTXOdyssey Therapeutics Inc.$19.36+1.15%$930.6M
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier